newsfilter
← Latest News
GlobeNewswire·

ProQR Announces Third Quarter 2025 Operating and Financial Results

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from